Exubera Lung Test Will Be Advised Until More Data Is Collected, FDA Says
A recommendation for patients taking Pfizer's Exubera to get lung function tests every six to 12 months will continue until the agency has more information on the product's effect on the lungs from post-marketing studies
You may also be interested in...
Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.
FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta